Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints...
March 08, 2023 19:00 ET | Source: Bionomics Ltd

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of...
February 23, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics’ Half-Year Report

ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented...
November 02, 2022 06:00 ET | Source: Bionomics Ltd

Bionomics Limited to Participate in Upcoming November Investor Conferences

ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
October 18, 2022 06:00 ET | Source: Bionomics Ltd

Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

ADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to announce that the...
July 29, 2022 06:00 ET | Source: Bionomics Ltd

Quarterly Activities Report for June 2022

ADELAIDE, Australia, July 29, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a global, clinical stage biopharmaceutical company, today released its...